About NOWDiagnostics
NOWDiagnostics is a Healthcare company based in Bentonville (United States) founded in 2013. It develops rapid assay medical tests that use a single drop of blood to test for a variety of common conditions, illnesses and diseases. NOWDiagnostics has raised $65.69 million across 5 funding rounds from investors including LabCorp, DigitalDX Ventures and Kompass Kapital. The company has 28 employees. NOWDiagnostics has completed 2 acquisitions, including Cellmic and ZBx Corporation. NOWDiagnostics offers products and services including First To Know® Syphilis Test, ADEXUSDx® hCG Test, and First To Know® Pregnancy Test (EU). Its focus areas include Life Sciences, Infectious Diseases, In Vitro Diagnostic Tests and Bacterial. Its legal entity is NOWDIAGNOSTICS INC. Its competitors include OpGen, Avails Medical and HandyLab; 3 of its 3 listed competitors have raised funding.
Company details
NowDiagnostics, formerly known as HomeDx develops and manufactures diagnostic tests that offer POC rapid test reader. Its ADEXUSDx product line uses a single drop of blood to test for a variety of common conditions, illnesses and diseases with quick results. It received FDA clearance for hCG test and is conducting two cardiac (heart attack) tests and three toxicology tests in Europe. Additional tests are in the development pipeline, including sexually transmitted diseases, more cardiac (heart attack), food intolerances, common infectious diseases and a variety of screening tests.
Products & Services of NOWDiagnostics
NOWDiagnostics offers a comprehensive portfolio of products and services, including First To Know® Syphilis Test, ADEXUSDx® hCG Test, and First To Know® Pregnancy Test (EU).
Over-the-counter test for rapid syphilis detection at home.
Home test for detecting pregnancy through hormone analysis.
Over-the-counter test for pregnancy in European markets.
Funding Insights of NOWDiagnostics
NOWDiagnostics has successfully raised a total of $65.69M across 5 strategic funding rounds. The most recent funding activity was a Series B round of $22.5 million completed in July 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $65.69M
- Total Rounds 5
- Last Round Series B — $22.5M
- First Round $25,000
(Mar 2013)
- Investors Count 3
All 5 funding rounds of NOWDiagnostics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2024 | $22.5M | Series B | – | DigitalDx Ventures, LabCorp | |
| Dec 2019 | $18.97M | Series A | – | – | – |
| Jun 2018 | $13.25M | Series A | – | – | – |
| Jul 2016 | $10.94M | Series A | – | – | – |
| Mar 2013 | $25,000 | Seed | – | – | – |
3 investors in total: 3 institutional.
Investors in NOWDiagnostics
NOWDiagnostics has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include LabCorp, DigitalDX Ventures and Kompass Kapital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
DigitalDX Ventures is focused on AI and healthcare innovation investments. | digitaldxventures.com | Menlo Park, United States | ||
Private fund focused on debt, equity, and fund of funds investments | kompasskapital.com | Overland Park, United States | ||
Provider of laboratory tests for physicians | 1969 | labcorp.com | Burlington, United States |
Investor details for NOWDiagnostics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of NOWDiagnostics
20 people are tracked at NOWDiagnostics (7 in leadership, 8 in board & advisors, 5 in team); the tracked headcount is 28.
| Name | Role | Group |
|---|---|---|
Kevin Clark | CEO | Leadership |
Gianni Furino | CEO, NOWDx Europe | Leadership |
T.j. Rivetti | Director Of Sales, Public Health | Leadership |
Vicki Thompson | Director of Product Development | Leadership |
Michele Roe | Director of Quality | Leadership |
John Miller | Chief Financial Officer | Leadership |
Jody D Berry | Chief Scientific Officer | Leadership |
Gregory H. Bledsoe | Advisor | Board & advisors |
Doug Degn | Director | Board & advisors |
Jeff Montie | Director | Board & advisors |
Charles Farkas | Director | Board & advisors |
John Adams | Director | Board & advisors |
Jeremy Wilson | Founder & Chairman | Board & advisors |
Jerry Gallwas | Director | Board & advisors |
John B. Harley | Director | Board & advisors |
Jianghong Qian | Senior Product Development Scientist | Team |
Conner Veit | Product Development Scientist | Team |
Sydney Spradlin | Engineering/production Manager | Team |
Bob Dill | Independent Sales Representative At Now Diagnostics | Team |
Gabriella Miller | Account Manager | Team |
Complete people profiles for NOWDiagnostics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by NOWDiagnostics
NOWDiagnostics has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Cellmic and ZBx Corporation.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Rapid test readers are developed for chromatographic and fluorescent assays. | cellmic.com | Los Angeles, United States | 2009 | Jul 2018 | •••• | |
Point-of-care diagnostic products for clinical testing are developed and marketed. | zbx.ca | Toronto, Canada | 2002 | Sep 2015 | •••• |
Complete acquisition details for NOWDiagnostics
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of NOWDiagnostics
5 dated milestones of NOWDiagnostics across 11 years, from founding to its latest funding, stage changes and deals.
- Founded NOWDiagnostics is founded.
- Funding First funding round of $25K.
- Acquisition Acquires ZBx Corporation.
- Acquisition Acquires Cellmic.
- Funding Latest funding round, Series B, of $22.5M.
Competitors of NOWDiagnostics
NOWDiagnostics has 3 listed competitors in our database, 3 of them funded. They include OpGen, Avails Medical and HandyLab.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| opgen.com | 2002 | Rockville, United States | $77.51M | 100 | Developer of diagnostics and bioinformatics platforms for providers | |
| availsmedical.com | 2013 | Menlo Park, United States | $8.66M | Point-of-care devices are developed for infection diagnosis and treatment optimization. | ||
| handylab.com | 1999 | Ann Arbor, United States | $30.7M | Molecular diagnostic assays and automation platforms are developed. |
Detailed competitors of NOWDiagnostics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of NOWDiagnostics
The website of NOWDiagnostics (nowdx.com) receives about 1.8K visits a month.
- Monthly visits1.8K
▼ 16.2% vs previous month
Top companies in Infectious Diseases
3 companies that operate in the same segment as NOWDiagnostics (Infectious Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 | |
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Nowdiagnostics
Complete news archive for NOWDiagnostics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about NOWDiagnostics
NOWDiagnostics was founded in 2013.
NOWDiagnostics is headquartered in Bentonville, United States. It is registered at Bentonville, Arkansas, United States.
NOWDiagnostics is a funded company, having raised a total of $65.69M across 5 funding rounds to date. The company's 1st funding round was a Seed of $25K, raised on Mar 2013.
NOWDiagnostics has 28 employees.
NowDiagnostics, formerly known as HomeDx develops and manufactures diagnostic tests that offer POC rapid test reader. Its ADEXUSDx product line uses a single drop of blood to test for a variety of common conditions, illnesses and diseases with quick results. It received FDA clearance for hCG test and is conducting two cardiac (heart attack) tests and three toxicology tests in Europe. Additional tests are in the development pipeline, including sexually transmitted diseases, more cardiac (heart attack), food intolerances, common infectious diseases and a variety of screening tests.
NOWDiagnostics's top competitors include Avails Medical, OpGen and HandyLab.
NOWDiagnostics offers First To Know® Syphilis Test, ADEXUSDx® hCG Test, and First To Know® Pregnancy Test (EU).
NOWDiagnostics has made 2 acquisitions, including Cellmic, and ZBx Corporation.
NOWDiagnostics has 3 investors. Key investors include LabCorp, DigitalDX Ventures, and Kompass Kapital.
NOWDiagnostics operates through Nowdiagnostics Inc..